ES2384208T3 - Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. - Google Patents
Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. Download PDFInfo
- Publication number
- ES2384208T3 ES2384208T3 ES06077149T ES06077149T ES2384208T3 ES 2384208 T3 ES2384208 T3 ES 2384208T3 ES 06077149 T ES06077149 T ES 06077149T ES 06077149 T ES06077149 T ES 06077149T ES 2384208 T3 ES2384208 T3 ES 2384208T3
- Authority
- ES
- Spain
- Prior art keywords
- vol
- cancer
- mmc
- bioreductive
- bladder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010005003 Bladder cancer Diseases 0.000 title claims description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title claims description 8
- 201000005112 urinary bladder cancer Diseases 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000002842 anticancer formulation Substances 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 101000973778 Homo sapiens NAD(P)H dehydrogenase [quinone] 1 Proteins 0.000 claims description 13
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 8
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 206010021143 Hypoxia Diseases 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 102000004316 Oxidoreductases Human genes 0.000 claims description 5
- 108090000854 Oxidoreductases Proteins 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 230000001146 hypoxic effect Effects 0.000 claims description 5
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- -1 1-aziridinyl Chemical group 0.000 claims description 3
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 3
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 3
- 108020000284 NAD(P)H dehydrogenase (quinone) Proteins 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 229960001904 epirubicin Drugs 0.000 claims description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 3
- 238000012552 review Methods 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000035572 chemosensitivity Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 230000008520 organization Effects 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000010198 papillary carcinoma Diseases 0.000 claims description 2
- 238000002271 resection Methods 0.000 claims description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Natural products C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 claims 5
- 235000001258 Cinchona calisaya Nutrition 0.000 claims 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 3
- 230000000144 pharmacologic effect Effects 0.000 claims 3
- 229960000948 quinine Drugs 0.000 claims 3
- 230000002152 alkylating effect Effects 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 238000009509 drug development Methods 0.000 claims 2
- 230000014509 gene expression Effects 0.000 claims 2
- 208000037841 lung tumor Diseases 0.000 claims 2
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 2
- 206010051779 Bone marrow toxicity Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000004960 NAD(P)H dehydrogenase (quinone) Human genes 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 231100000366 bone marrow toxicity Toxicity 0.000 claims 1
- 201000010989 colorectal carcinoma Diseases 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000013115 immunohistochemical detection Methods 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 8
- 238000000034 method Methods 0.000 abstract description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 abstract 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012143 endoscopic resection Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Una formulación anticancerígena que comprende: a) (5-(1-aziridinyl)-3-(hidroximetil)-2-[(E)-3-hidroxiprop-1-enil]-1-metil-1H-indol-4,7-dione] (E09); y b) glicol de propileno.
Description
ANTECEDENTES DE LA INVENCION
[0001] El cáncer de vejiga representa aproximadamente el 2% de todos los cánceres malignos y es el quinto y el décimo cáncer más común en hombres y mujeres, respectivamente. La Sociedad Americana del Cáncer estimó que 54.500 nuevos casos y 11.700 muertes se habrían producido en 1997. Los cánceres superficiales de vejiga (pTa, pT1 y CIS) responden del 70 -80% de la primera realización del cáncer. El control del cáncer superficial de vejiga puede conseguirse mediante cirugía de resección endoscópica seguida a menudo por un tratamiento de quimioterapia intravesical auxiliar o inmunoterapia con el objetivo de erradicar las células tumorales celulares restantes y evitar la recurrencia del tumor (Herr HW (1987) Intravesical therapy-a critical review. Urol Clin N Am 14: 399-404). Ambos anti-neoplásicos (Mitomicina C [MMC], epirubicina y tioTHEPA) y la inmunoterapia (BCG), administrados intravesicalmente son eficaces en la reducción de la tasa de recidiva del tumor, aunque no está claro si se evita la progresión de la enfermedad a tumores invasivos del músculo (Newling D (1990) Terapia Intravesical en el control del carcinoma de células superficiales transicionales de la vejiga, experiencia del grupo EORTC GU, Br J Cancer 61:497-499; Oostenink et al. (1993) Un ensayo aleatorio prospectivo del Grupo de la Organización Europea para Investigación y Tratamiento del Cancer Genitourinario comparando la resección transuretral seguida de una instilación única de epirubicina o agua en una sola etapa Ta, carcinoma papilar T1 de la vejiga. J Urol 149:749-752). Esta observación junto con el hecho de que la mortalidad por cáncer de vejiga sigue siendo alta subraya la necesidad de desarrollar más agentes terapéuticos eficaces (Oosterlink et al. 1993).
[0002] Un agente terapéutico tal es el MMC que pertenece a una clase de compuestos conocidos como medicamentos bioreductores (Workman 1994). MMC representa uno de los agentes antineoplásicos utilizados para tratar el cáncer superficial de vejiga (Maffezzini et al, 1996, Tolley et al. 1996). MMC es activado a una especie citotóxica por reductasas celulares aunque el papel de las enzimas reductasas específicas implicadas en la activación bioreductiva sigue siendo poco definido y controvertido (Cummings et al, 1998a). Esto es particularmente cierto para la enzima NQ01 (NAD (P) H: Quinona oxidorreductasa, EC 1.6.99.2), que es una flavoproteína citosólica que cataliza la reducción de dos electrones de varios compuestos a base de quinona utilizando NADH o NADPH como donantes de electrones (Schlager y Powis. 1988, Siegel et al, 1990). El compuesto estructuralmente relacionado E09 (5 - (1-aziridinilo) -3 - (hidroximetil) -2 [(E)-3-hidroxiprop-] 1-enil-1-metil-1H-indol-4] ,7-diona, es sin embargo un sustrato mucho mejor para NQO1 que MMC (Walton et al 1991), y existe una buena correlación entre la actividad NQO1 y la quimiosensibilidad in vitro en condiciones aeróbicas (Robertson et al, 1994, Fitzsimmons et al, 1996, Smitkamp-Wilms et al, 1994). Bajo condiciones de hipoxia sin embargo, las propiedades de E09 son muy diferentes con poca o ninguna potenciación de la toxicidad de E09 observada en células ricas en NQO1 (Plumb y Workman, 1994). En las líneas celulares deficientes en NQ01 sin embargo, se han encontrado grandes proporciones de citotoxicidad hipóxica (Workman, 1994). Por lo tanto, E09 tiene el potencial para aprovechar la fracción aeróbica de los tumores ricos en NQ01 o la fracción aeróbica de los tumores deficientes en NQO1 (Workman, 1994).
[0003] E09 ha sido evaluado clínicamente pero a pesar de los informes de tres remisiones parciales en los ensayos clínicos de fase, ninguna actividad fue observada en contra de NSCLC, cáncer gástrico, de mama, de páncreas y el cáncer de colon en posteriores estudios de fase II (Schellens et al, 1994, Dirix et al, 1996). Estos hallazgos son especialmente decepcionantes a la vista de los estudios preclínicos (Hendriks et al, 1993) junto con los informes que varios tipos de tumores tienen niveles elevados de NQO1 (Malkinson et al, 1992, Smitkamp-al de Wilms y otros, 1995, Siegel et al, 1998). Varias explicaciones posibles han sido propuestas para explicar la falta de eficacia clínica del E09 (Connors, 1996, Phillips et al, 1998). Estudios recientes han demostrado que el fallo de E09 en la clínica puede no ser debido a las malas interacciones farmacodinámicas pero puede ser el resultado de la mala administración de fármacos a los tumores (Phillips et al, 1998). La eliminación rápida en plasma de la E09 (t1/2= 10 min en los seres humanos) junto con la escasa penetración a través de capas multicelulares sugiere que el E09 no penetrará más de unas pocas micras de un vaso sanguíneo dentro de su vida útil farmacocinética (Schellens et al, 1994, Phillips y otros, 1998). La administración intratumoral de E09 a los tumores ricos y deficientes en NQO1 produjo importantes retrasos de crecimiento (aunque una distinción entre el daño a la fracción aeróbica o hipóxica no ha sido determinada), sugiriendo que si E09 puede ser administrado para los tumores, se pueden conseguir efectos terapéuticos (Cummings et al, 1998b). Si bien estas características indeseables son un serio revés para el tratamiento de la enfermedad sistémica, paradójicamente, pueden ser ventajosas para el tratamiento de cánceres que se presentan en un tercer compartimiento, como el cáncer superficial de vejiga. En este escenario, la administración del medicamento no es problemática por la ruta intravesical y la penetración de la E09 en el tejido avascular puede incrementarse por el mantenimiento terapéutico de concentraciones importantes de medicamentos dentro de la vejiga (usando un periodo de instilación de una hora por ejemplo). Mientras que este método de instilación E09 dentro de la vejiga puede ser útil, todavía sigue siendo una necesidad de vehículos de administración del medicamento capaces de entregar una cantidad eficaz de E09 dentro de la vejiga.
[0004] JD de Vries et al (Int J Farmacia, 100 (1993) 181-188) investigaron la estabilidad química del E09 utilizando un ensayo en fase inversa indicador de estabilidad de HPLC con detecciones UV y espectrofotometría UV. La cinética de degradación del E09 fue estudiada como una función de pH, composición del tampón, fuerza iónica y temperatura.
[0005] JD Jonkman-de Vries et al (Quimioterapia del cáncer Pharmacol (1994) 34:416-422) informó de un estudio para diseñar una forma de dosificación parenteral estable de E09. El estudio investigó la atomización de soluciones acuosas de E09.
[0006] Choudry et al (Br J Cancer (2001) 85 (8), 1137-1146) describe composiciones para el tratamiento de cáncer de vejiga, estas composiciones incluyen E09. Este documento estudia la relación entre la actividad NQO1 en el tejido tumoral y selectividad de E09. Además, Choudry at al enseña que la entrega de E09 en un vehículo acídico resulta en una mayor actividad dentro de la vejiga con cualquier fármaco absorbido en el torrente sanguíneo volviéndose relativamente inactivo debido al aumento en el pH. Sin embargo, este documento no discute métodos para la estabilización de una composición E09 reconstituida.
BREVE RESUMEN DE LA INVENCION
[0007] De acuerdo con la presente invención, se provee una formulación contra el cáncer tal como se define en la Reivindicación 1, comprendiendo EO9 y glicol de propileno.
[0008] De acuerdo con la presente invención, la composición de la presente invención comprende E09 y un agente de recubrimiento que es glicol de propileno. El agente de recubrimiento permite una mejor adherencia de la composición a la pared de la vejiga. En consecuencia, la composición y, en particular, el E09 contacta y puede ser capaz de penetrar en el tejido avascular que comprende por un tiempo suficiente para tratar el cáncer de vejiga.
DESCRIPCION DETALLADA DE LA INVENCION
[0009] Las realizaciones de la presente invención están dirigidas a composiciones para el tratamiento de cáncer de vejiga vía instilación intravesical. Se divulga aquí una composición que comprende5-(1-aziridinilo)-3-(hidroximetil)-2-[(E)-3-hidroxiprop-1-enil]-1-metil-1H-indol-4,7-dion a (E09) y un vehículo de formulación. Los vehículos de formulación son disolventes que mejoran la solubilidad y estabilidad de EO9.
[0010] Según una realización ejemplar, la formulación anti-cáncer puede ser preparada usando un vehículo reconstituyente que consta de 2% de bicarbonato de sodio, 0,02% edetato disódico y glicol de propileno: agua (60:40 V/V). Este vehículo de reconstitución disuelve la composición liofilizada y produce una solución estable para administración de hasta 24 horas. Adicionalmente, el vehículo de reconstitución proporciona una ampolla teniendo un volumen extraíble de 5 ml de E09 reconstituído comprendiendo glicol de propileno/agua/bicarbonato de sodio/edetato de sodio 60/40/2/0.02% vlv/p/p.
Choudry GA, Hamilton Stewart PA, Double JA, Krul MRL, Naylor B, Flannigan GM, Shah TK, Brun JE y Phillips RM (2001); A novel strategy for NQO1 (NAD(P)H: quinine oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of E09. Br J Cancer 85 (8) 1137-1146.
Connors TA (1996) Bioreductive agents, hypoxic cells and therapy. Eur J Cancer 32A: 1833-1834.
Cummings J, Spanswick VJ, Tomaz M and Smyth JF (1998a) Enzymology of MMC metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development Biochem Pharmacol 56: 405-414.
Cummings J, Spanswick VJ, Gardiner J, Ritchie A and Smyth, IF (1998b) Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone E09. Biochem Pharmacol 55: 253-260.
Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, Huinink WWT, Pavlidis N, Sorio R, Gamucci T, Wolff I, Tevelde A, Lan J, and Verweij J (1996) E09 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the early clinical studies group. Eur J Cancer 32A: 2019-2022.
Fitzsimmons S A, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to MMC and E09. J Natl Cancer Inst 88: 259-269 Gutierrez PL (1989) Mechanism of bioreductive alkylation. The example of diazaquinone (AZQ. Free Radical Bio Med 6: 405-445.
Hendriks HR. Piazo PE, Berger DP, Kooistra KL, Bibby MC, Boven E, Dreef-Van Der Meulen HC, Henrar-REC, Fiebig HH, Double JA, Homstra HW, Pinedo HM, Workman P and Swartsmann G (1993) E09: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A: 897-906.
Herr HW (1987) Intravesical therapy - a critical review. Urology Clinics of N America 14: 399-404.
Maffezzini M, Simonata A, Zanon M, Raber M and Carmig ani G (1996) Up-front chemotherapy for low stage low grade recurrent bladder cancer. J Urol 155; 91-93 . Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD and Ross D (1992) Elevated NQO1 activity and messenger RNA content in human non small cell lung carcinoma - Relationship to the response of lung tumor xenografts to MMC. Cancer Res 52: 4752-4757.
Newling D (1990) Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group. Br J Cancer 61: 497-499.
Oosterlink W, Kurth KH, Schr6der F, Bultinck J, Hammond B, Sylvester R, and members of the European Organisation for Research and Treatment of Cancer Genitourinary
Phillips RM, Loadman PM and Cronin BP (1998) Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumors. Br J Cancer 77: 2112-2119.
Plumb JA and Workman P (1994) Unusually marked hypoxic sensitisation to indoloquinone E09 and MMC in a human colon tumor cell line that lacks NQOI activity. Int J Cancer 56: 134-139.
Robertson N, Haigh A, Adams GE and Stratford U (1994) Factors affecting sensitivity to E09 in rodent and human tumor cells in vitro: NQO1 activity and hypoxia. Eur J Cancer 30A: 1013-1019.
Schellens JHM, Planting AST, Van Acker BAC, Loos WJ, De Boer-Dennert M, Van Der Burg MEL, Koier I, Krediet RT, Stoter G and Verweij J (1994) Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst 86: 906-912.
Schlager JJ and Powis G (1988) MMC is not metabolized by but is an inhibitor of human kidney NAD(P) H:(quinone acceptor) oxidoreductase. Cancer Chemother Pharmacol 22: 126-130.
Siegel D, Franklin WA and Ross D (1998) Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res 4: 2065-2070.
Smitkamp-Wilms E, Peters GJ, Pinedo HM, Van Arkotte J and Giaccone G (1994) Chemosensitivity to the indoloquinone E09 is correlated with NQ01 activity and gene expression. Biochem Pharmacol 47: 1325-1332.
Smitskamp-Wlms E, Giaccone G, Pinedo HM, Van Der Laan BFAM and Peters GJ (1995) NQO1 activity in normal and neoplastic human tissues: An indicator of sensitivity to bioreductive agents ?. Br J Cancer 72: 917-921.
Tolley DA, Parmar MKB, Grigor KM, Lallemand G and the Medical Research Council superficial bladder cancer working party (1996) The effect of intravesical MMC on recurrence of newly diagnosed superficial bladder cancer A further report with 7 years of followup. J Urol 155: 1233-1238.
Walton MI, Smith PJ and Workman P (1991) The role of NAD(P)H:quinone reductase (EC 1.6.99.2, NQ01) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. CancerCommun 3: 199-206.
Workman P (1994) Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer drugs and quinone metabolizing enzymes, particularly NQO1. Oncol Res 6: 461-475.
Claims (2)
- Reivindicaciones
- 1.
- Una formulación anticancerígena que comprende: a) (5-(1-aziridinyl)-3-(hidroximetil)-2-[(E)-3-hidroxiprop-1-enil]-1-metil-1H-indol-4,7-dione] (E09); y b) glicol de propileno.
-
- 2.
- Una formulación anticancerígena según la reivindicación 1 que comprende una dosis unitaria de 8 mg de E09.
REFERENCIAS CITADAS EN LA DESCRIPCION Esta lista de referencias citadas por el solicitante es solamente para conveniencia del lector. No forman parte del documento de la patente europea. Aún cuando la compilación de referencias se ha hecho con sumo cuidado, errores u omisiones no pueden ser excluidas y la EPO declina toda responsabilidad en este aspecto.Bibliografía citada en la descripción que no forma parte de la patente.- •
- Herr HW. Intravesical therapy-a critical review. Urol Clin N Am, 1987, vol. 14, 399-404 [0001]
- •
- Newling D. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder the experience of the EORTC GU group. Br J Cancer,1990, vol. 61, 497-499 [0001]
- •
- Oostenink et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol, 1993, vol. 149, 749-752 [0001]
- •
- J D de Vries et al. Int J Pharmaceutics, 1993, vol. 100, 181-188 [0004]
- •
- J D Jonkman-de Vries et al. Cancer Chemother Pharmacol, 1994, vol. 34, 416-422 [0005]
- •
- Choudry et al. Br J Cancer, 2001, vol. 85 (8), 1137-1146 [0006]
- •
- Choudry GA ; Hamilton Stewart PA ; Double JA ; Krul MRL ; Naylor B ; Flannigan GM ; Shah TK ; Brun JE ; Phillips RM. A novel strategy for NQO1 (NAD(P)H: quinine oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of E09. Br J Cancer, 2001, vol. 85 (8), 1137-1146 [0010]
- •
- Connors TA. Bioreductive agents, hypoxic cells and therapy. Eur J Cancer, 1996, vol. 32A, 1833-1834 [0010]
- •
- Cummings J ; Spanswick VJ ; Tomaz M ; Smyth JF. Enzymology of MMC metabolic activation in tumor tissue. Implications for enzyme directed bioreductive drug development. Biochem Pharmacol, 1998, vol. 56, 405-414 [0010]
- •
- Cummings J ; Spanswick VJ ; Gardiner J ; Ritchie A ; Smyth, IF. Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone E09. Biochem Pharmacol, 1998, vol. 55, 253-260 [0010]
- •
- Dirix LY ; Tonnesen F ; Cassidy J ; Epelbaum R ; Huinink WWT ; Pavlidis N ; Sorio R ; Gamucci T ; Wolff I ; Tevelde A. E09 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the early clinical studies group. Eur J Cancer, 1996, vol. 32A, 2019-2022 [0010]
- •
- Fitzsimmons S A ; Workman P ; Grever M ; Paull K ; Camalier R ; Lewis AD. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to MMC and E09. J Natl Cancer Inst, 1996, vol. 88, 259-269 [0010]
- •
- Gutierrez PL. Mechanism of bioreductive alkylation. The example of diazaquinone (AZQ. Free Radical Bio Med, 1989, vol. 6, 405-445 [0010]
- •
- Hendriks HR ; Piazo PE ; Berger DP ; Kooistra KL ; Bibby MC ; Boven E ; Dreef-Van Der Meulen
HC ; Henrar-REC ; Fiebig HH ; Double JA. E09: A novel bioreductive alkylating indoloquinone with preferential solid tumor activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer, 1993, vol. 29A, 897-906 [0010]- •
- Herr HW. Intravesical therapy - a critical review. Urology Clinics of N America, 1987, vol. 14, 399-404 [0010]
- •
- Maffezzini M ; Simonata A ; Zanon M ; Raber M ; Carmig ani G. Up-front chemotherapy for low stage low grade recurrent bladder cancer. J Urol, 1996, vol. 155, 91-93 [0010]
- •
- Malkinson AM ; Siegel D ; Forrest GL ; Gazdar AF ; Oie HK ; Chan DC ; Bunn PA ; Mabry M ; Dykes DJ ; Harrison SD. Elevated NQO1 activity and messenger RNA content in human non small cell lung carcinoma - Relationship to the response of lung tumor xenografts to MMC. Cancer Res, 1992, vol. 52, 4752-4757 [0010]
- •
- Newling D. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group. Br J Cancer, 1990, vol. 61, 497-499 0010]
- •
- Phillips RM ; Loadman PM ; Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumors. Br J Cancer,1998, vol. 77, 2112-2119 [0010]
- •
- Plumb JA ; Workman P. Unusually marked hypoxic sensitisation to indoloquinone E09 and MMC in a human colon tumor cell line that lacks NQOI activity. Int J Cancer, 1994, vol. 56, 134-139 [0010]
- •
- Robertson N ; Haigh A ; Adams GE ; Stratford U.Factors affecting sensitivity to E09 in rodent and human tumor cells in vitro: NQO1 activity and hypoxia. Eur J Cancer, 1994, vol. 30A, 1013-1019 [0010]
- •
- Schellens JHM ; Planting AST ; Van Acker BAC ; Loos WJ ; De Boer-Dennert M ; Van Der Burg MEL ; Koier I ; Krediet RT ; Stoter G ; Verweij J. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09. J Natl Cancer Inst, 1994, vol. 86, 906-912 [0010]
- •
- Schlager JJ ; Powis G. MMC is not metabolised by but is an inhibitor of human kidney NAD(P)H:(quinine acceptor) oxidoreductase. Cancer Chemother Pharmacol,1988, vol. 22, 126-130 [0010]
- •
- Siegel D ; Franklin WA ; Ross D. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res, 1998, vol. 4, 2065-2070 0010]
- •
- Smitkamp-Wilms E ; Peters GJ ; Pinedo HM ; Van Arkotte J ; Giaccone G. Chemosensitivity to the indoloquinone E09 is correlated with NQ01 activity and gene expression. Biochem Pharmacol, 1994, vol. 47,1325-1332 [0010]
- •
- Smitskamp-Wlms E ; Giaccone G ; Pinedo HM ; Van Der Laan BFAM ; Peters GJ. NQO1 activity in normal and neoplastic human tissues: An indicator of sensitivity to bioreductive gents ?. Br J Cancer, 1995, vol. 72, 917-921 [0010]
- •
- Tolley DA ; Parmar MKB ; Grigor KM ; Lallemand G. The effect of intravesical MMC on recurrence of newly diagnosed superficial bladder cancer A further report with 7 years of followup.
J Urol, 1996, vol. 155, 1233-1238 [0010] • Walton MI ; Smith PJ ; Workman P. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, NQ01) in the reductive bioactivation of the novel indoloquinone antitumour agent E09. CancerCommun, 1991, vol. 3, 199-206 [0010]- •
- Workman P. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinine anticancer drugs and quinone metabolising enzymes, particularly NQO1. Oncol Res, 1994, vol. 6, 461-475 [0010]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34444601P | 2001-11-01 | 2001-11-01 | |
| US344446P | 2001-11-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2384208T3 true ES2384208T3 (es) | 2012-07-02 |
Family
ID=23350584
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES06077149T Expired - Lifetime ES2384208T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. |
| ES09075067T Expired - Lifetime ES2341922T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicas para el tratamiento intravesical de cancer de vejiga. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES09075067T Expired - Lifetime ES2341922T3 (es) | 2001-11-01 | 2002-11-01 | Composiciones medicas para el tratamiento intravesical de cancer de vejiga. |
Country Status (12)
| Country | Link |
|---|---|
| US (6) | US6894071B2 (es) |
| EP (3) | EP1439835A2 (es) |
| JP (1) | JP4317452B2 (es) |
| AT (2) | ATE493126T1 (es) |
| AU (1) | AU2002350115A1 (es) |
| CA (2) | CA2466148C (es) |
| CY (1) | CY1111252T1 (es) |
| DE (2) | DE60238798D1 (es) |
| DK (2) | DK1864660T3 (es) |
| ES (2) | ES2384208T3 (es) |
| PT (2) | PT2060259E (es) |
| WO (1) | WO2003037314A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2384208T3 (es) * | 2001-11-01 | 2012-07-02 | Spectrum Pharmaceuticals, Inc. | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. |
| US8563592B2 (en) * | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
| US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
| AU2006230582A1 (en) * | 2005-03-31 | 2006-10-05 | Spectrum Pharmaceuticals, Inc. | Indoloquinone tumor radiation sensitization |
| WO2006130978A1 (en) | 2005-06-06 | 2006-12-14 | The University Of British Columbia | Polymer-based serum albumin substitute |
| US20070203112A1 (en) * | 2006-02-09 | 2007-08-30 | Phillips Roger M | Bladder cancer treatment and methods |
| CA2669138A1 (en) * | 2006-11-09 | 2008-12-04 | University Of Maryland, Baltimore | Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent |
| BRPI0808804A2 (pt) * | 2007-03-13 | 2014-08-19 | Spectrum Pharmaceuticals Inc | Administração de apaziquona intravesical seguindo ressecção transuretral para tratamento de câncer |
| RU2354386C1 (ru) * | 2007-12-26 | 2009-05-10 | ГУ Московская городская онкологическая больница №62 Департамента здравоохранения г. Москвы | Способ профилактики рецидивов поверхностного рака мочевого пузыря |
| GB0800311D0 (en) * | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
| DK2525777T3 (da) | 2010-01-20 | 2019-07-01 | Urogen Pharma Ltd | Materiale og fremgangsmåde til at behandle interne hulrum |
| BR112012021991A2 (pt) | 2010-03-01 | 2020-09-01 | The University Of British Columbia | policlicerol hiperramificado uso de um poliglicerol hipermanificado, método de adiministração de uma força biologicamente ativa a um tecido biológico, composição farmacêutica e método de síntese de um poliglicerol hiperrramificado. |
| NO2619331T3 (es) * | 2010-09-22 | 2018-07-28 | ||
| WO2013011504A1 (en) | 2011-07-20 | 2013-01-24 | Theracoat Ltd. | Materials and method for treating internal body cavities |
| JP6495654B2 (ja) | 2011-10-24 | 2019-04-03 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | シクロヘキシルアミン類 |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| JP6616772B2 (ja) | 2013-12-16 | 2019-12-04 | アサナ・バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー | Ｐ２ｘ３および／またはｐ２ｘ２／３化合物ならびに方法 |
| CN104743887B (zh) * | 2014-09-22 | 2016-03-23 | 巨石集团有限公司 | 一种玻璃纤维组合物及其玻璃纤维和复合材料 |
| IL265648B2 (en) | 2016-09-30 | 2025-07-01 | Asana Biosciences Llc | p2x3 and/or p2x2/3 modulatory compounds and their uses |
| US20220107320A1 (en) | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
| CN112220742A (zh) * | 2019-07-15 | 2021-01-15 | 深圳艾欣达伟医药科技有限公司 | 稳定的ast-3424注射液制剂及制备方法 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) * | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| JPS54151134A (en) | 1978-05-19 | 1979-11-28 | Kureha Chem Ind Co Ltd | Antitumorigenic agent |
| NL8001280A (nl) * | 1980-03-04 | 1981-10-01 | Philips Nv | Lagedrukontladingslamp. |
| DE3486448T2 (de) | 1983-11-14 | 1997-10-09 | Columbia Lab Inc | Bioadhäsive Mittel |
| US4898729A (en) | 1983-12-09 | 1990-02-06 | Euroceltique, S.A. | Treatment of hypertension, compounds and compositions for antihypertension and diuresis |
| US4671954A (en) * | 1983-12-13 | 1987-06-09 | University Of Florida | Microspheres for incorporation of therapeutic substances and methods of preparation thereof |
| JPS60163621A (ja) | 1984-02-02 | 1985-08-26 | 村上 俊文 | 紙製便座カバ−の製造方法 |
| JPS60163821A (ja) | 1984-02-03 | 1985-08-26 | Tdk Corp | フエライト粒子を含む薬剤用担体 |
| JPS61189215A (ja) | 1985-02-18 | 1986-08-22 | Teijin Ltd | ５−フルオロ−２′−デオキシウリジンエステル類の油状医薬組成物 |
| DE3782938T2 (de) * | 1986-04-17 | 1993-10-21 | Everardus Arnoldus Oostveen | Indochinon-verbindungen. |
| US4871542A (en) * | 1987-04-30 | 1989-10-03 | Ferring Service Center, N.V. | Method and apparatus useful for delivering medicinal compositions into the bladder and urinary tract |
| EP0331635A3 (en) | 1988-02-29 | 1990-02-28 | The Board of Regents of the University of Texas System | Preparations for treating bladder cancer |
| EP0338679A3 (en) | 1988-03-24 | 1991-03-06 | Genentech, Inc. | Tumour necrosis factor in the treatment of bladder cancer |
| FR2629584B1 (fr) | 1988-03-31 | 1993-06-04 | France Etat Armement | Dispositif de stabilisation pour un projectile a faible moment d'inertie longitudinal tire a partir d'un tube raye |
| US5843156A (en) * | 1988-08-24 | 1998-12-01 | Endoluminal Therapeutics, Inc. | Local polymeric gel cellular therapy |
| US5744166A (en) * | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| PT93772A (pt) * | 1989-04-17 | 1991-01-08 | Searle & Co | Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer |
| US5216011A (en) * | 1989-09-01 | 1993-06-01 | Bristol-Myers Squibb Co. | Stable solutions of mitomycin c |
| US5237466A (en) | 1989-11-02 | 1993-08-17 | International Business Machines Corporation | Method and apparatus for programmably controlling spindle synchronization and phase among disk drives in a storage subsystem |
| FI84874C (fi) | 1989-11-02 | 1992-02-10 | Valio Meijerien | Foerfarande foer inkapsling av biologiskt aktiva aemnen, enligt metoden framstaelld kapsel, dess anvaendning och foder innehaollande den. |
| US5292516A (en) * | 1990-05-01 | 1994-03-08 | Mediventures, Inc. | Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers |
| US5346703A (en) * | 1990-08-07 | 1994-09-13 | Mediventures, Inc. | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
| IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
| US5550110A (en) | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| JP3598049B2 (ja) | 1992-09-18 | 2004-12-08 | 山之内製薬株式会社 | ハイドロゲル徐放性製剤 |
| US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| ATE192932T1 (de) | 1993-09-09 | 2000-06-15 | Takeda Chemical Industries Ltd | Formulierung enthaltend einen antibakteriellen und einen antiulcus wirkstoff |
| CA2135151A1 (en) | 1993-11-08 | 1995-05-09 | Mitsuhiro Wakimasu | Cyclic hexapeptides, their production and use |
| US5405622A (en) * | 1993-12-22 | 1995-04-11 | Vernice; Joseph | Gamma radiation resistant lubricating gel |
| TW438601B (en) * | 1994-05-18 | 2001-06-07 | Janssen Pharmaceutica Nv | New mucoadhesive emulsion compositions and a process for the preparation thereof |
| US5811416A (en) | 1994-06-06 | 1998-09-22 | Board Of Regents The University Of Texas System | Endothelin antagonist and/or endothelin synthase inhibitor in combination with a progestin, an estrogen, a cyclooxygenase inhibitor, or a nitric acid donor or substrate |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| MX9703988A (es) | 1994-12-12 | 1998-02-28 | Omeros Med Sys Inc | SOLUCIaN Y MÉTODO DE IRRIGACIaN PARA LA INHIBICIaN DEL DOLOR, LA INFLAMACIaN Y ES ESPASMO. |
| US5749845A (en) * | 1995-01-25 | 1998-05-12 | Iotek, Inc. | Delivering an agent to an organ |
| WO1997023456A1 (en) | 1995-12-21 | 1997-07-03 | British Technology Group Ltd. | Indoloquinone derivatives as bioreductive agents |
| US5985312A (en) | 1996-01-26 | 1999-11-16 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers |
| AU712953B2 (en) * | 1996-03-11 | 1999-11-18 | Focal, Inc. | Polymeric delivery of radionuclides and radiopharmaceuticals |
| US5955096A (en) * | 1996-06-25 | 1999-09-21 | Brown University Research Foundation | Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients |
| US6251861B1 (en) | 1996-06-27 | 2001-06-26 | Takeda Chemical Industries, Ltd. | Treatment of cerebral infarction using cyclic hexapeptides |
| JP2967734B2 (ja) * | 1996-10-18 | 1999-10-25 | 日本電気株式会社 | 薄膜の形成方法 |
| AU6876498A (en) * | 1997-04-03 | 1998-10-22 | Point Biomedical Corporation | Intravesical drug delivery system |
| US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
| WO1999012547A1 (en) * | 1997-09-08 | 1999-03-18 | Theramark Limited | Treatment of inflammatory conditions |
| US6156744A (en) | 1998-03-19 | 2000-12-05 | Cancer Research Campaign Tech (London) | DT-diaphorase directed anti-tumor agents |
| EP0950418A2 (en) | 1998-04-14 | 1999-10-20 | Takeda Chemical Industries, Ltd. | Composition for preventing or treating ischemic disease |
| US6171610B1 (en) * | 1998-04-24 | 2001-01-09 | University Of Massachusetts | Guided development and support of hydrogel-cell compositions |
| EP1075261B1 (en) | 1998-05-05 | 2006-04-12 | AstraZeneca AB | Mycobacterial inhibitors |
| IL124957A0 (en) | 1998-06-16 | 1999-01-26 | Univ Ben Gurion | Active ingredient delivery systems and devices based on porous matrices |
| US6087396A (en) * | 1998-10-05 | 2000-07-11 | Situs Corporation | Oxybutynin formulations and method of use |
| GB9827034D0 (en) | 1998-12-10 | 1999-02-03 | Univ Manchester | Delivery formulation |
| JP2000256182A (ja) | 1999-03-03 | 2000-09-19 | Kazuhiro Morimoto | 抗菌製剤 |
| DE60013591T2 (de) | 1999-04-29 | 2005-02-03 | Coley Pharmaceutical Gmbh | Screening nach modulatoren der funktion von immunstimulatorischer dna |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| MXPA02010764A (es) | 2000-05-31 | 2003-03-10 | Warner Lambert Co | Combinaciones de un antagonista del receptor endotelina y un compuesto antiepileptico que tiene propiedades para aliviar el dolor o analgesico. |
| DE60142921D1 (de) | 2000-12-01 | 2010-10-07 | Eisai Inc | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren |
| US6573285B2 (en) | 2000-12-21 | 2003-06-03 | Bristol-Myers Squibb Co. | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030104976A1 (en) | 2001-07-23 | 2003-06-05 | Gudarz Davar | Analgesic methods using endothelin receptor ligands |
| ES2384208T3 (es) | 2001-11-01 | 2012-07-02 | Spectrum Pharmaceuticals, Inc. | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. |
| US7973064B2 (en) | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| AU2003223925A1 (en) | 2002-05-03 | 2003-11-17 | Novo Nordisk A/S | Stabilised solid compositions of modified factor vii |
| US20040009918A1 (en) | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| JP2006508086A (ja) | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
| ES2460517T3 (es) | 2005-07-25 | 2014-05-13 | Emergent Product Development Seattle, Llc | Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20 |
| US20070203112A1 (en) | 2006-02-09 | 2007-08-30 | Phillips Roger M | Bladder cancer treatment and methods |
-
2002
- 2002-11-01 ES ES06077149T patent/ES2384208T3/es not_active Expired - Lifetime
- 2002-11-01 US US10/285,783 patent/US6894071B2/en not_active Expired - Lifetime
- 2002-11-01 EP EP02786643A patent/EP1439835A2/en not_active Withdrawn
- 2002-11-01 CA CA2466148A patent/CA2466148C/en not_active Expired - Fee Related
- 2002-11-01 DE DE60238798T patent/DE60238798D1/de not_active Expired - Lifetime
- 2002-11-01 AT AT06077149T patent/ATE493126T1/de active
- 2002-11-01 DE DE60235214T patent/DE60235214D1/de not_active Expired - Lifetime
- 2002-11-01 DK DK06077149.0T patent/DK1864660T3/da active
- 2002-11-01 DK DK09075067.0T patent/DK2060259T3/da active
- 2002-11-01 EP EP06077149A patent/EP1864660B1/en not_active Expired - Lifetime
- 2002-11-01 JP JP2003539658A patent/JP4317452B2/ja not_active Expired - Lifetime
- 2002-11-01 CA CA2789114A patent/CA2789114C/en not_active Expired - Fee Related
- 2002-11-01 PT PT09075067T patent/PT2060259E/pt unknown
- 2002-11-01 AT AT09075067T patent/ATE455545T1/de active
- 2002-11-01 WO PCT/US2002/035191 patent/WO2003037314A2/en not_active Ceased
- 2002-11-01 PT PT06077149T patent/PT1864660E/pt unknown
- 2002-11-01 EP EP09075067A patent/EP2060259B1/en not_active Expired - Lifetime
- 2002-11-01 ES ES09075067T patent/ES2341922T3/es not_active Expired - Lifetime
- 2002-11-01 AU AU2002350115A patent/AU2002350115A1/en not_active Abandoned
-
2005
- 2005-04-01 US US11/096,566 patent/US20050215615A1/en not_active Abandoned
-
2006
- 2006-09-13 US US11/531,535 patent/US20070010570A1/en not_active Abandoned
-
2008
- 2008-03-21 US US12/053,418 patent/US7977369B2/en not_active Expired - Fee Related
- 2008-12-03 US US12/327,781 patent/US20090076123A1/en not_active Abandoned
-
2011
- 2011-02-14 CY CY20111100183T patent/CY1111252T1/el unknown
-
2012
- 2012-06-11 US US13/493,911 patent/US8648108B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2384208T3 (es) | Composiciones medicinales para el tratatamiento intravesical del cáncer de vejiga. | |
| ES2305134T3 (es) | Utilizacion de cci-779 como un agente antineoplasico. | |
| Shmeeda et al. | Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells | |
| US9872834B2 (en) | Nanocarrier therapy for treating invasive tumors | |
| Thangavel et al. | Redox nanoparticle increases the chemotherapeutic efficiency of pioglitazone and suppresses its toxic side effects | |
| US20040009957A1 (en) | Protective effects of PDE-5 inhibitors | |
| Steinberg et al. | Intravesical valrubicin in the treatment of carcinoma in situ of the bladder | |
| HK1109875A1 (en) | Medical compositions for intravesical treatment of bladder cancer | |
| HK1109875B (en) | Medical compositions for intravesical treatment of bladder cancer | |
| JP2010539135A (ja) | 癌を治療するためのリポソーム製剤 | |
| US20050042275A1 (en) | Epothilone compositions | |
| EP1653948B1 (en) | Use of 5-methoxytryptamine as a cardioprotective agent | |
| Nisticò et al. | Weekly epirubicin plus lonidamine in advanced breast carcinoma | |
| Richard et al. | Delivery of ROS Generating Anthraquinones Using Reduction‐Responsive Peptide‐Based Nanoparticles | |
| HK1132181B (en) | Medical compositions for intravesical treatment of bladder cancer | |
| Bansal | Pharmacokinetic and Biodistribution Analysis of 5-Fluorouracil-and Celecoxib-loaded Eudragit S100-coated Chitosan Microspheres Intended for Colon-specific Delivery | |
| JP2004529893A (ja) | 改善されたバイオアベイラビリティーを有する組成物 | |
| Kulkarni et al. | Supramolecular nanoparticles that target phosphatidylinositol-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy | |
| Hendricksen et al. | Adjuvant intravesical pharmacotherapy for non-muscle invasive bladder cancer |